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Discovery of the Inhibitory Effect of a Phosphatidylinositol
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Followed by In Vitro Cellular Studies
Xavier Lucas1", Silke Simon2", Rolf Schubert2, Stefan Gu¨nther1*
1 Pharmaceutical Bioinformatics, Institute of Pharmaceutical Sciences, Albert-Ludwigs-University, Freiburg, Germany, 2 Pharmaceutical Technology and Biopharmacy,
Albert-Ludwigs-University, Freiburg, Germany
Abstract
P-glycoprotein is capable of effluxing a broad range of cytosolic and membrane penetrating xenobiotic substrates, thus
leading to multi-drug resistance and posing a threat for the therapeutic treatment of several diseases, including cancer and
central nervous disorders. Herein, a virtual screening campaign followed by experimental validation in Caco-2, MDKCII, and
MDKCII mdr1 transfected cell lines has been conducted for the identification of novel phospholipids with P-gp
transportation inhibitory activity. Phosphatidylinositol-(1,2-dioctanoyl)-sodium salt (8:0 PI) was found to significantly inhibit
transmembrane P-gp transportation in vitro in a reproducible-, cell line-, and substrate-independent manner. Further tests
are needed to determine whether this and other phosphatidylinositols could be co-administered with oral drugs to
successfully increase their bioavailability. Moreover, as phosphatidylinositols and phosphoinositides are present in the
human diet and are known to play an important role in signal transduction and cell motility, our finding could be of
substantial interest for nutrition science as well.
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Introduction
Around 5% of the human genes are involved in lipid synthesis
and regulation. Not surprisingly, these biomolecules have crucial
biological functions: They are the primary component of the
cellular membrane, can act as first and second messengers in signal
transduction and molecular recognition processes, and serve as
energy storage [1]. Moreover, they modulate the activity of
transporter membrane proteins, like the (ATP)-binding cassette P-
glycoprotein (P-gp). Substrates transported by P-gp are highly
diverse, mostly from amphipathic and neutral or weakly basic
nature, and including compounds ranging in molecular weight
from less than 200 Da to almost 1900 Da [2]. As a result, the
transporter is capable of effluxing a broad range of cytosolic
xenobiotic substrates, thus affecting the absorption of several types
of drugs and eventually leading to multi-drug resistance (MDR)
[3,4]. In fact, there is strong evidence of the role of P-gp in the
development of diseases and addictions [5–8], posing a real threat
for their therapeutic treatment. During the last decades, inhibition
of P-gp has been used as a mechanism to combat MDR in cancer
therapy, and many small molecules modulating its activity have
been described [9,10]. Examples of such molecules include the
calcium channel blocker verapamil, natural products like quini-
dine and the immunosuppressive agent cyclosporine A, and other
surfactants and amphiphilic substances [11–13]. Even though the
exact molecular mechanisms have yet to be completely elucidated,
P-gp inhibition is mainly due to tightly binding and blocking the
transmembrane substrate binding pockets or by inhibition of the
ATPase activity of the cytoplasmic nucleotide-binding domain
[2,14]. Inhibition can also be induced by allosteric modulation
with substances binding to non-substrate binding sites within the
transmembrane regions or by interaction with the P-gp surround-
ing cell membrane [15–17]. Recently, the modulation of ATPase
activity and transport inhibition of several phospholipids, includ-
ing phosphatidylcholine (PC), -ethanolamine (PE), -glycerol (PG),
and -serine (PS) derivatives, has been studied at the cellular level.
Two phosphatidylcholine derivatives, namely 8:0 PC and
10:0 PC, have been found to significantly reduce ATPase activity
and inhibit membrane transport of P-gp substrates [18].
Phosphatidylinositols and their phosphorylated adducts play a
key role in many biological processes, e.g. signal transduction and
cytokinesis [19–22]. However, their role in substrate transporta-
tion by P-gp has not yet been studied.
P-glycoprotein consists of two a-helical transmembrane do-
mains (TMDs), and two nucleotide binding domains (NBDs)
(Fig. 1). The TMDs contain the substrate-binding sites and the
translocation conduit [23]. Different binding sites for xenobiotics
or drugs have been described, as well as the possibility of allocating
two molecules simultaneously [24,25]. Drug transport by P-gp is
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driven by a switch between two main conformational states of the
NBD dimer: ATP binding to the drug-binding competent state
induces a rotation of the NBDs and adoption of a close
conformation, whereas ATP hydrolysis leads back to the open
conformation of the dimer. The close conformation mediates
substrate translocation in the TMDs drug-binding sites, thus
triggering the release of the substrate to the extracellular face of
the membrane [26]. The elucidation of the 3D structure of mouse
P-gp in the drug-binding competent state allows for the virtual
screening and rational design of modulators of human P-gp [27].
In the present manuscript, a virtual screening experiment followed
by in vitro cellular assays was carried out for the identification of
novel phospholipids with ability to modulate transmembrane
transportation by P-gp.
Materials and Methods
Target Generation
Three crystal structures of P-gp in the drug-binding competent
conformation from Mus musculus are available so far (PDB IDs:
3G5U, 3G60, and 3G61 [27]). As they show a low structural
difference [28], we utilized the best resolved 3G5U apo-P-gp
structure as a template to generate a homology model for the
human transporter (Fig. 1, protein model included in PDB format
as Supplementary Material), using the software Prime 2.2
(Schro¨dinger, LLC, New York, USA). Model quality was assessed
using the Swiss-Model server [29]. The whole inner intermem-
brane region of the transporter was subjected to a computational
molecular binding analysis. The quality of the model was assessed
by performing molecular docking experiments with the known
inhibitors Elacridar and Verapamil (XP scores of210.9 and29.9,
respectively). We further used experimental Caco-2 results to study
the prediction capabilities of our docking model, and observed
70% accuracy in the discrimination between active and inactive
phospholipid molecules (Table S2).
Library Preparation
We used an in-house instance of the workflow management
system Galaxy [30] to generate a ligand library containing 178
distinct phospholipids with chain length $6 of the phosphatidyl-
choline (PC), -ethanolamine (PE), -glycerol (PG), -inositol (PI),
-serine (PS) and phosphatidic acid (PA) compound classes by
performing substructure searches (query scaffolds shown in Table
S1) on the Dictionary of Natural Products [31], ChEMBL [32],
and ZINC [33] libraries. Those compounds were duly processed
using LigPrep 2.4 (Schro¨dinger, LLC, New York, USA) at
pH 6.562.0, for the sake of consistency with the buffered
experimental validation process.
Docking Experiment
Molecular docking calculations on the human transporter
model were performed with Glide 5.6 (Schro¨dinger, LLC, New
York, USA) using the eXtra Precision (XP) docking algorithm with
extended sampling, to ensure an accurate treatment of the
inherent flexibility of mainly large, unsaturated lipid chains.
Statistical analysis of the top 18 molecules (10% of the library, see
Results and Discussion section and Fig. S1) led to the selection of 4
candidate phospholipid derivatives that were subsequently pur-
chased for further experimental analysis.
Materials
Phosphatidylinositol-1,2-dioctanoyl-sodium salt (PtdIns 8:0-Na,
8:0 PI) and phosphatidylinositol-(5)-P1-1,2-dihexanoyl-sodium salt
(PtdIns P1 6:0-Na, 6:0 PIP1) were purchased from Cayman
Chemical Company, Inc. (Ann Arbor, Michigan, USA). 1-
Stearoyl-2-oleoyl-sn-glycero-3-phosphate-sodium salt (18:0/
18:1 PA) and 1,2-dimyristoyl-sn-glycero-3-phosphate-sodium salt
(14:0 PA, DMPA) were purchased from Avanti Polar Lipids, Inc.
(Alabaster, Alabama, USA).
Statistical Analysis of the in vitro Assays
We applied One-Way ANOVA combined with Tukey and
Levene’s test using the OriginPro 8.1G (Origin Lab) software to
determine significant effects of lipid formulations compared to
positive (verapamil) or negative control samples (buffer). Further
details on the statistical methods along with the experimental
setting have been already described elsewhere [18].
Results and Discussion
Herein, we performed a virtual screening campaign for the
discovery of novel phospholipids with cell transport activity (see
Methods). Among the possible mechanisms described for P-gp
inhibition [34], we focused on molecules that would either
sterically block, allosterically modulate, or compete with other
substrates of interest; therefore we took into consideration the
TMDs of the transporter. Figure 1 depicts the homology model
built for human P-gp. The transmembrane region of the
transporter, subjected to the molecular docking experiment, shows
a very high sequence identity. Regions of the protein exposed to
the intra- and extracellular spaces present a lower conservation.
This model exhibited 70% accuracy in the discrimination between
active and inactive phospholipids in docking studies (Table S2).
Thus, a total of 178 distinct molecules of the PA, PC, PE, PG, PI,
and PS compound classes were virtually tested on the substrate-
binding domain of the transporter. Interestingly, phospholipids of
Figure 1. Homology model of human P-gp used in the
molecular docking experiment. Tube width and residue colouring
depict sequence conservation, ranging from thin and blue (identity) to
wide and red (null conservation). Compound 8:0 PI upon binding to the
substrate channel is shown in purple spheres. Location of P-gp in the
cellular membrane and the TMDs and NBDs are indicted.
doi:10.1371/journal.pone.0060679.g001
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the previously unreported PI class very significantly accumulated
on the top 10% of the screening results (see Table 1), suggesting a
preference of the transporter to interact with phosphatidylinositol
derivatives. From those 18 top-ranked molecules, PA derivatives
accumulated significantly but to a lesser extent. Docking poses of
the other phosphatidyl classes did not accumulate significantly
within the top scoring range (XP scores from 212 to 215). These
findings led to the selection of two purchasable candidate
compounds of each of the PI and PA classes for further
experimental in vitro testing, namely 8:0 PI, 6:0 PIP1, 18:0/
18:1 PA, and 14:0 PA (Fig. 2).
The binding mode obtained for compound 8:0 PI in the
substrate binding pocket of human P-gp indicates that its polar
head group entangles in hydrogen-bond interactions with Asn721,
Gln725, and Gln990 (Fig. S2). These polar residues define a
positively charged region on the protein surface (Fig. S3, coloured
in blue) that surrounds the acidic and inositol moieties of the lipid,
while the aliphatic fatty acid chains remain in lipophilic cavities of
the pocket (mainly coloured in white or pale). Indeed, most of the
pocket is of hydrophobic nature, accounting for the promiscuous
behaviour of the transporter [2]. Notably, the analysis of the
location of the phosphate group in the rest of the top-ranked 18
molecules allowed for the identification of a favoured region for
phosphate positioning in a cavity defined by the TM7 and TM12
a-helixes, in the asymmetric protein’s substrate pocket (Fig. S3,
[27]). The phosphate group of 8:0 PI precisely locates in the
identified favoured region.
Characterisation of the Lipid Formulations by DLS and
Cryo-TEM
Depending on their structure, phospholipids can occur in a wide
range of aggregation states when dispersed in an aqueous medium:
dissolved as monomers, aggregated to small disordered structures,
or as clearly defined vesicles, i.e. liposomes [18]. A key factor is the
chain length of the fatty acid residues, since chains shorter than 6–
8 carbon atoms hamper vesicle formation due to the decreased
hydrophobic interactions within the lipid bilayer. Another
influence is exerted by the polar head group: Charged structures
induce strong repulsive forces between lipid monomers, leading to
unstable aggregates, if any.
This circumstance could be also confirmed with Cryo-Trans-
mission Electron Microscopy (Cryo-TEM) for the derivatives
tested in the current study (Fig. 3). The long-chained 18:0/
18:1 PA formed vesicles in demineralised water, but of a very
broad size distribution (Table S3). Given that the tested
compounds were formulated as sodium-salts, the negatively
charged phosphate group might have prevented intensive vesicle
formation due to intermolecular electrostatic repulsive forces. In
the case of PI derivatives, presenting much shorter carbon chains
in addition to the negatively charged head group, the liposomal
aggregation is rather unlikely. Indeed, this hypothesis is in
agreement with Dynamic Light Scattering (DLS) measurements
(Table S3), as the PDI values exceeded the limit of 0.8, therefore
impeding meaningful size determinations. Figure 3b verifies that a
8:0 PI ( = PtdIns 8:0-Na) formulation of 1.0 mM in demineralised
water contained neither vesicles nor aggregates. Thus, we
concluded that 8:0 PI occurred as a solubilized monomer.
Transport Studies across Caco-2 Monolayers
We studied the interference of our candidate compounds with
the transport capabilities of the P-gp substrate digoxin, by
measuring the differential flux of the transport marker across a
cell layer, due to significant changes in secretion or absorption
(Fig. 4 and Table S4). As transport medium we chose isotonic
hank’s balanced salt solution (HBSS) pH 6.5. Digoxin transport
(1 mM; partially 3H-labelled) in untreated human colon carcinoma
(Caco-2) cell layers was distinctly asymmetric, the secretory flux
exceeding roughly by 12-fold the absorptive one (control). This
accounted for the distinct expression of the efflux transporter,
especially as the substrate flux was nearly equalized after pre-
Figure 2. Candidate compounds selected for experimental validation. a) Phosphatidylinositol-1,2-dioctanoyl-sodium salt, 8:0 PI or PtdIns
8:0-Na. b) Phosphatidylinositol-(5)-P1-1,2-dihexanoyl-disodium salt, 6:0 PIP1 or PtdIns P1 6:0-Na. c) 1-Stearoyl-2-oleoyl-sn-glycero-3-phosphate-sodium
salt, 18:0/18:1 PA. d) 1,2-Dimyristoyl-sn-glycero-3-phosphate-sodium salt, 14:0 PA.
doi:10.1371/journal.pone.0060679.g002
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incubation with the established P-gp inhibitor verapamil. Caco-2
cells are a well-established biopharmaceutical tool to investigate
absorption processes across the human intestinal mucosa; there-
fore, these transport studies are of high importance to predict oral
bioavailability enhancement due to P-gp inhibition [35,36].
In the case of phosphatidic acid derivatives (Fig. 4a), no
alteration of digoxin transport was observed after pre-incubation
with 14:0 PA at 0.1 mM. Increase of the lipid amount led to a
reduction of the apparent permeability (Papp) ratio value by 30%.
However, this increase in concentration provoked a drop to 63%
in transepithelial electrical resistance (TEER), indicating a
disruption of the cell monolayer. The unsaturated PA derivative,
18:0/18:1 PA, did not show any potency in inhibition of digoxin
transport, even at a high concentration of 0.3 mM. These
observations do not agree with the in silico predictions. However,
docking studies were conducted with the respective lipid monomer
and any aggregation, such as vesicle formation or other possible
polymeric interferences, was not taken into account. Since both
PA derivatives present long, mainly saturated fatty acid chains,
they tend to form lipid aggregates, as depicted in Fig. 3a [37].
Previous studies have shown that phospholipids might interact
with P-gp preferentially in their monomeric state [18], thus
compounds with a low monomeric concentration might not be
able to cause observable transporter inhibition.
Figure 4b features the modulation produced in the digoxin
transportation by human P-gp in Caco-2 studies after pre-
incubation with our candidate phosphatidylinositol derivatives.
Interestingly, 8:0 PI ( = PtdIns 8:0-Na) induced a significant (45%)
reduction of Papp ratio at 0.1 mM combined with a TEER value
within the acceptable limit. A 2-fold increase in lipid concentration
promoted a stronger inhibition of transportation, but at the
expense of destroying the cell integrity nearly completely. No effect
on transportation was observed after pre-incubation with 6:0 PIP1.
Table 1. Phospholipid class distribution for the in silico results.
Phospholipid class Representatives in top 10% Total amount in library p1
PA 5 28 0.04*
PC 2 58 0.97
PE 1 29 0.83
PG 0 9 0.63
PI 9 21 1.4?1026***
PS 1 18 0.57
Others2 0 15 0.81
Total 18 178 –
Classification in PA, PC, PE, PG, PI, and PS (phosphatidic acid, phosphatidylcholine, -ethanolamine, -glycerol, -inositol, and -serine, respectively). The statistical
significance p of each observation is shown.
1Probability p computed using the hypergeometric distribution.
2Due to substructure-based searches, some of the phospholipid substitutions clearly differentiate from the main scaffolds.
*indicates a statistical significance p,0.05.
***indicates a statistical significance p,0.001.
doi:10.1371/journal.pone.0060679.t001
Figure 3. Cryo-TEM screenshots of selected phospholipid formulations. a) 18:0/18:1 PA vesicles in demineralised water, prepared via film
method and ultra-sonication (15 min; 30 W); lipid conc. = 4.3 mM. b) 8:0 PI ( = PtdIns 8:0-Na) in demineralised water, prepared via film method and
extrusion through polycarbonate membranes (21680 nm pore size); lipid conc. = 1.0 mM.
doi:10.1371/journal.pone.0060679.g003
Inhibition of P-gp by Phosphatidylinositols
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Figure 4. Apparent permeability (Papp) ratio of digoxin transport in Caco-2 cells. Digoxin flux was measured in pure HBSS pH 6.5 (Control)
and after 30 min of pre-incubation with verapamil or liposomal formulations of phosphatidic acid and phosphatidylinositol derivatives in buffer (top
and bottom, respectively); n = 3; results are given as mean+standard deviation (*: significance level: 0.05 compared to control; **: significance level:
0.01 compared to control).
doi:10.1371/journal.pone.0060679.g004
Inhibition of P-gp by Phosphatidylinositols
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The striking and singular efficacy of 8:0 PI might be related to
its caprylic moiety, also found in 8:0 PC, which was recently
identified as well as active in inhibiting P-gp transportation [18].
Moreover, this short fatty acid chain increases the critical micelle
concentration of the lipid, leading to a comparably high monomer
amount in the formulation (Fig. 3b). Another key aspect of the
compound’s activity could be explained by analysing its binding
pose (Fig. S2). Axial hydroxyl groups at positions C2 and C3 of the
myo-inositol moiety of 8:0 PI are involved in hydrogen-bond
interactions with Gln725, accounting for specific and unique
interactions that would increase ligand affinity. The location of the
compound upon binding, as shown in Figure 1, indicates that
8:0 PI inhibits P-gp apical transportation by tightly binding and
blocking its TMDs.
Calcein Accumulation Assay (CAA)
After obtaining indications for P-gp modulation activity for
8:0 PI in Caco-2 studies, it was further subjected to CAA, which
detects the P-gp-dependent intracellular accumulation of the
fluorescent dye calcein. This assay was performed in parallel in a
parental wild type (wt) Madin Darby canine kidney (MDCK) II
cell line with basal P-gp expression and its corresponding P-gp-
overexpressing strain, which is stably transfected with human mdr1.
In this test, the degree of P-gp-inhibition directly correlates with
the entrapped amount of calcein and, thus, the intensity of
intracellular fluorescence. Given that P-gp expression level is the
unique difference between both MDCKII strains, different
increases in fluorescence intensity in the mdr1 transfected and wt
clearly indicate true P-gp modulation [38].
Figure 5 summarizes the results of CAA using HBSS pH 6.5 as
assay buffer. The fluorescence intensities of each cell line treated
solely with the calcein-derivative were set to 100% (= control).
With the other intensity values referring to this control, an
enhancement due to P-gp inhibition became visible. Incubation
with the positive control verapamil (0.5 mM) led to an increase in
intracellular fluorescence by 1.5-fold in wt cells and 7-fold in mdr1.
This difference in effect verified the true impact of Verapamil on
the P-gp transporter. The same effect can be observed for 8:0 PI
( = PtdIns 8:0-Na), inducing a 3.8-fold increase in calcein
accumulation in the overexpressing strain, but only an 1.8-fold
enhancement in wt.
These results indicate that 8:0 PI exerts a reproducible-, cell
line-, and substrate-independent P-gp inhibition.
Conclusions
In the present manuscript we have conducted a virtual
screening campaign for the identification of novel phospholipids
capable of inhibiting cellular membrane transportation by P-gp.
Compounds of the previously unstudied phosphatidylinositol class
were identified as potential binders by molecular docking analysis
(Table 1). The experimental validation of 4 candidate compounds,
namely 18:0/18:1 PA, 14:0 PA, 6:0 PIP1, and 8:0 PI, led to the
discovery of the latter as an active modulator of P-gp transpor-
tation. 8:0 PI exerted a significant transportation inhibition of the
substrate digoxin in Caco-2 cells, which was subsequently
unequivocally correlated to P-gp modulation in comparative
MDCKII CAA studies (Fig. 4 and 5). Moreover, this compound
showed a high tendency to exist as a monomer in solution (Fig. 3b),
which has been described as a favoured state for P-gp inhibition
[18]. Even though several possible mechanisms have been
formulated for the inhibition of this transporter, our hypothesis
–based on the assumptions of our theoretical model– is that 8:0 PI
modulates transportation either by steric blockade of the substrate-
binding domain, by allosteric modulation or by competition with
other transported substrates (Fig. 1, [34]).
All in all, the identification of compounds that inhibit P-gp
transportation is particularly interesting for their implications in
combating multi-drug resistance. In fact, the co-administration of
P-gp inhibitors along with P-gp substrate drugs might be a
promising option in pharmacological formulation development in
Figure 5. Calcein Accumulation Assay results. Relative intracellular calcein fluorescence signal in MDCKII mdr1 and wild type (wt) cells (in grey
and black, respectively) after pre-incubation with verapamil or 8:0 PI ( = PtdIns 8:0-Na) in HBSS with respect to the control (100% RF; calcein-
acetoxymethylester in HBSS); n = 6; results are given as mean+standard deviation (*: significance level: 0.05 compared to control; **: significance level:
0.01 compared to control; ***: significance level: 1023 compared to control).
doi:10.1371/journal.pone.0060679.g005
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order to overcome drug resistance. Moreover, and due to the
important role of phosphatidylinositols and phosphoinositides in
many biological processes, such as cell motility and signalling [19–
22], the unexpected discovery of the P-gp inhibitory properties of
8:0 PI may account for a natural mechanism of regulation of
cellular membrane function and xenobiotic efflux. Currently,
several biological functions of exogenous PI are known, including
inhibition of vascular endothelial growth factor (VEGF)-induced
angiogenesis, inhibition of low concentrations of amyloid b protein
induced degeneration, and promotion of cholesterol transport and
excretion eventually inducing anti-obesity response in mice [39–
43]. As phospholipids are a common constituent of human diet –
for example, phosphoinositols are found in significant amounts in
soybean–, it becomes important to further characterise and
analyse their role in transmembrane transportation, and study
their possible effects in in vivo models for combating MDR.
Supporting Information
Figure S1 Distribution of XP scores in the molecular
docking experiment. The vertical line at x = 18 indicates the
top 10% of the results.
(TIF)
Figure S2 Inter-molecular hydrogen-bond interactions
(as yellow dashed lines) present in the predicted pose of
8:0 PI (in purple sticks) in the substrate-binding pocket
of human P-gp (in grey cartoon). Interacting residues
(Asn721 and Gln725 from TM7 a-helix, and Gln990 from
TM12) are highlighted.
(TIF)
Figure S3 Location of the phosphorus atom of the
phosphatidyl group in the top-ranked 18 compounds
upon docking in the substrate binding pocket of human P-
gp, depicted as coloured spheres (the colouring scheme
identifies the compound class, see legend and Table S1
for details). For reference purposes, the binding pose of 8:0 PI is
shown in thin purple sticks. Protein surface coloured by electrostatic
potential: positive in blue, neutral in white, and negative in red.
(TIF)
Table S1 Representation of the chemical scaffolds used
as query for the substructure searches (PA, PC, PE, PG,
PI, and PS stand for phosphatidic acid, phosphatidyl-
choline, -ethanolamine, -glycerol, -inositol, and -serine,
respectively).
(DOCX)
Table S2 Comparison of experimental and predicted
values used for validation of the theoretical model. Their
relative Papp ratio, XP score, and the consistency of predicted and
experimental results are shown.
(DOCX)
Table S3 Hydrodynamic diameter and polydispersity
index (PDI) of the applied phospholipid formulations
measured via Dynamic Light Scattering. Values given as
mean 6 standard deviation from three measurements (21 single
runs).
(DOCX)
Table S4 Papp ratio of tested compounds (referred to
the control value) and impact on TEER in Caco-2
transport studies.
(DOCX)
File S1 Homology model of the human P-gp transport-
er.
(PDB)
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